Our Pipeline

Advancing Controlled Metabolic Accelerators, a New Class of Oral Medicines

We are developing a new class of oral investigational medicines called Controlled Metabolic Accelerators (CMAs), designed to safely increase metabolic rate to achieve sustained, fat-selective, muscle-preserving weight loss. 

With a robust dataset spanning three Phase 2 clinical trials, our lead candidate HU6 (an ANT-channel activator) has demonstrated positive results and well-tolerated safety and tolerability profiles across MASH (metabolic dysfunction associated steatohepatitis), MASLD (metabolic dysfunction-associated steatotic liver disease), and HFpEF (heart failure with preserved ejection fraction). In clinical trials, HU6 has demonstrated fat-selective, muscle-preserving weight loss as well as improvements in cardiovascular risk markers.

For HU6, Rivus has completed Phase 2 clinical trials in MASH and MASLD, with MASLD data published in The Lancet Gastroenterology & Hepatology. In addition, Rivus has completed a Phase 2 clinical trial in patients with HFpEF, which was published in JAMA Cardiology. As a near-term focus, Rivus plans to advance HU6 in a next Phase 2 trial in MASH, a serious disease driven by obesity and a growing public health issue for which new therapeutic options are urgently needed.

Beyond HU6, Rivus has a pipeline of novel CMAs in preclinical development for obesity and cardiovascular disease, including RV-300 (dual ANT-GLP-1 pharmacology). RV-300 is an oral small molecule in preclinical development that is designed to work on both the sides of the energy equation - by increasing energy expenditure with the CMA mechanism and by caloric restriction with the GLP-1 mechanism.